Q-omics provides the consensus-scored HMGN2P16 profile across patient tissues and cancer cell-line models. HMGN2P16 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in MESO. Additionally, HMGN2P16 RNA expression shows 6,490 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, and STAD as cancer lineages where HMGN2P16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.